{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:05:52Z","timestamp":1792058752083,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although the combination of tyrosine kinase inhibitors with chemotherapy is widely used for young adults with Philadelphia chromosome positive\u2010acute lymphoblastic leukaemia (Ph+ <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>), the outcome and safety of this combination using intensive paediatric\u2010based protocols has not been well described. The clinical course of 32 adults age 18\u201360\u00a0years with Ph+ <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> treated with a paediatric\u2010based protocol plus imatinib was evaluated. The complete response rate was 94%. Grade 3\u20134 infections, neuropathy, myopathy and liver function abnormalities were common, resulting in major treatment delays and dose reductions, and declines in performance status (physical deconditioning), particularly in patients aged 41\u201360\u00a0years. Median and 3\u2010year overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) was 40\u00b77\u00a0months and 53%, respectively, and median and 3\u2010year even\u2010free survival (<jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>) was 30\u00b71\u00a0months and 50%, respectively. <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content> were inferior in deconditioned patients. Of 16 patients who underwent haematopoietic stem cell transplantation (<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) in first complete remission, six died of non\u2010relapse complications. There was no significant difference in <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content> between transplanted and non\u2010transplanted patients, based on an intention\u2010to\u2010treat and time\u2010to\u2010donor identification analysis. The combination of imatinib with a paediatric\u2010based regimen in adults produced high response rates, but was associated with considerable toxicity and high non\u2010relapse mortality post\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2012.09182.x","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T06:51:15Z","timestamp":1338533475000},"page":"506-514","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of Philadelphia chromosome\u2010positive acute lymphoblastic leukaemia with imatinib combined with a paediatric\u2010based protocol"],"prefix":"10.1111","volume":"158","author":[{"given":"Santhosh","family":"Thyagu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.L.","family":"Yee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans A.","family":"Messner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Princess Margaret Hospital University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Brandwein","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.05.015"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1287"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-259358"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.506873"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24862"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.015974"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.11.023"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.4081\/pr.2011.s2.e2"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351403"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0772-y"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.300"},{"key":"e_1_2_6_14_1","first-page":"8","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR\u2010ABL transcripts and kinase domain mutations and for expressing results","volume":"2","author":"Hughes T.","year":"2006","journal-title":"Blood 2006, 108"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403886"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00946.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011221"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.11.024"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07712.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2958"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052746"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4386"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.197"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2177"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2012.09182.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2012.09182.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:09:12Z","timestamp":1700543352000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2012.09182.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2141.2012.09182.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09182.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"2012-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}